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Introduction: Early identification of preventable risk factors of COPD progression is 
important. Whether exacerbations have a negative impact on disease progression is largely 
unknown. We investigated whether the long-term occurrence of exacerbations is associated 
with lung function decline at early stages of COPD.
Methods: Patients diagnosed with mild/moderate COPD (obstruction and FEV1% predicted 
50–90%), aged ≥35 years, and a smoking history, who had ≥6 years of UK electronic 
medical records after initiation of maintenance therapy were studied. Multilevel mixed- 
effect linear regression was performed to determine the association between the count of 
any year in which the patient had ≥1 exacerbation over a 6-year period and FEV1 decline, 
adjusted for sex, age, anthropometrics and smoking habits. Exacerbations were defined as 
any prescription for an acute oral corticosteroid course and/or lower respiratory-related 
antibiotics and/or any COPD-related emergency or inpatient hospitalization.
Results: Of 11,337 patients included (mean age 65 years; 49% female) 31.6%, 23.3%, 
16.6%, 11.6%, 8.1%, 5.3% and 3.4% had 0, 1, 2, 3, 4, 5 and 6 years with ≥1 exacerbation. 
The mean annual FEV1 decline accelerated by 1.50 mL/year (95% Confidence Interval 1.02; 
1.98) with every additional year with ≥1 exacerbation from 31.0 mL/year in subjects without 
any exacerbation to 40.0 mL/year in patients experiencing ≥1 exacerbation every year. 
Patients with more years with ≥1 exacerbation had a lower mean FEV1 at first diagnosis: 
14.7 mL (11.7; 17.8) lower with every additional year with exacerbations. When counting 
years with ≥2 exacerbations, greater effects were observed (2.19 [1.50; 2.88]  mL/year excess 
decline per year with ≥2 exacerbations; 16.5 mL [12.1; 20.8] lower FEV1 at diagnosis).
Conclusion: Patients who experienced a greater exacerbation burden after initiation of 
maintenance therapy had worse lung function at diagnosis and a more rapid lung function 
decline thereafter, which emphasizes the need for better treatment strategies.
Keywords: COPD, exacerbations, spirometry, inhalation therapy, observational study
Plain Language Summary
Patients with chronic obstructive pulmonary disease (COPD) may experience exacerbations, 
episodes of acute worsening of symptoms (also known as lung attacks), which may deteriorate 
lung function. Maintenance inhalation therapy may prevent exacerbations in some patients, but 
many patients continue experiencing exacerbations despite therapy. This study was conducted to 
investigate whether information on the long-term exacerbation burden, measured by counting the 
number of years over a 6-year period that patients had exacerbations despite maintenance therapy, 
can help identifying patients with more accelerated lung function decline at early stages of COPD. 
Using data from two large electronic medical record databases in the UK, the researchers found that 
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patients with more exacerbations after initiation of maintenance 
therapy had worse lung function at the time of first diagnosis and 
a more rapid lung function decline thereafter. The results, therefore, 
emphasize the need for more precise and aggressive intervention at an 
earlier stage of COPD to delay lung function loss. 
Introduction
Chronic obstructive pulmonary disease (COPD) is 
a chronic and debilitating respiratory disease characterized 
by progressively declining irreversible airflow limitation. 
It constitutes a global public health burden, associated 
with substantial morbidity and mortality.1 The WHO esti-
mated that 65 million people have moderate-severe COPD, 
accounting for 5% of all causes of death in 2005.2
COPD is a heterogeneous condition with a high degree of 
variation in the clinical presentation and rate of disease pro-
gression among individuals. Early life exposures and smoking 
are important factors predicting lung function in adult life.1 
However, why in some patients lung function declines rapidly 
and in others not is not well understood.3 In particular, the role 
of the burden of COPD in terms of occurrence of exacerba-
tions, events of acute worsening of COPD symptoms, on 
disease progression needs to be further studied. Whether 
a high exacerbation burden early in the disease may lead to 
accelerated decline has not been fully elucidated. However, 
there is sparse evidence that COPD exacerbations are asso-
ciated with subsequent accelerated lung function decline, par-
ticularly in those with mild disease.4 Lung function decline is 
most accelerated at the early stages of COPD5,6 and early 
identification of patients at risk followed by effective treatment 
of exacerbations may therefore be important.
Understanding the impact of treatment on exacerbation 
burden and ultimately disease progression was thus the 
aim of this study. We studied whether the long-term bur-
den of COPD exacerbations occurring after initiation of 
maintenance therapy is associated with lung function 
decline at early stages of COPD.
Methods
Data Source
This is a historical cohort study using primary care data 
from the Optimum Patient Care Research Database 
(OPCRD; https://opcrd.co.uk/) and the Clinical Practice 
Research Datalink (CPRD (protocol number 17_117); 
http://www.cprd.com/). The OPCRD is an anonymized, 
longitudinal medical record database of over 8 million 
patients from 700 primary care practices across the UK 
with a linked patient-completed respiratory questionnaire.7 
It houses high-quality, validated data used regularly in 
clinical, epidemiological, and pharmaceutical research 
and is approved by the Health Research Authority of the 
UK National Health Service for clinical research use 
(Research Ethics Committee reference: 15/EM/0150). 
The CPRD is a well-validated computerized database fre-
quently used for medical and health research, containing 
de-identified, longitudinal medical records of over 
11 million active patients from UK primary care practices. 
Coded diagnosis of COPD within the databases utilized 
that of Quality and Outcomes Framework (QOF) which 
has been previously validated.8
Study Design and Patients
Patient inclusion and exclusion criteria for this study are 
detailed in Table 1. The list of Read Codes used in this 
study is available upon request.
Table 1 Inclusion and Exclusion Criteria
Inclusion Criteria
● Diagnostic Read Code (Coding system used in the UK) for 
COPD.
● Valid spirometry recorded in the period between 3 months 
before and 12 months after the first diagnostic Read code for 
COPD. Date of the spirometry designated as the index date.
● Evidence of obstruction ever recorded, ie, FEV1/Forced Vital 
Capacity (FVC)<0.7.
● Mild to moderate airflow limitation at the time of first clinical 
diagnosis, ie, FEV1% predicted ≥50% and ≤90% at index date, as 
there is limited scope for further FEV1 decline and early inter-
vention in patients with more severe airflow limitation.
● Age ≥35 years
● ≥1 year of continuous medical records prior to the index date 
for baseline characterization
● ≥6 years of continuous medical records following the start of 
any maintenance therapy
● ≥1 FEV1 recording after index date
● A history of tobacco smoking (ex or current) at the time of first 
COPD diagnosis, ie, at any recording of smoking status prior to 
diagnosis or at first recording after diagnosis
● Height recorded within 5 years of index date and weight at adult 
age (≥21 years)
Exclusion criteria
● Active asthma at or after the date of first COPD diagnosis, 
defined as ≥1 diagnostic Read code for asthma, or ≥1 asthma 
monitoring or review code recorded, or asthma-COPD overlap 
syndrome as first COPD diagnostic code or recorded during 
follow-up
● Diagnostic code for other chronic lower respiratory conditions 
recorded ever
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All recorded FEV1 values were used to estimate lung 
function decline during follow-up. The date of the FEV1 
recording at time of diagnosis (defined as date of spiro-
metry within 3 months before to 12 months after COPD 
diagnosis) was chosen as the index date to characterize 
patients. At least one year of data prior to the index date 
was used for baseline characterization.
The primary outcome was the annual decline in FEV1 
during spirometry follow-up, expressed in mL per year. 
FEV1 (in mL) at index date (around time of first recorded 
clinical COPD diagnosis) was a secondary outcome.
We studied the association between the count of 
any year in which the patient had ≥1 exacerbation over 
a 6-year period following the date at which maintenance 
therapy was initiated and the outcomes. Maintenance ther-
apy included any of the following therapy prescribed dur-
ing follow-up as a single inhaler or in combination: 
inhaled corticosteroids (ICS), long-acting β2-agonist 
(LABA) or long-acting muscarinic antagonist (LAMA).
Exacerbations were defined as a prescription for acute 
oral corticosteroids and/or a respiratory-related antibiotic 
course and/or an emergency or inpatient hospitalization. 
Analyses were also performed for the number of years 
with frequent exacerbations (≥2 exacerbations per year, 
as per GOLD definition).1
Statistical Analysis
Statistical analyses were performed in Stata version 14.2 
(StataCorp, College Station, TX). Descriptive statistics 
were summarized for baseline characteristics. Categorical 
variables were presented as numbers and proportions and 
continuous variables as mean with standard deviation or 
median with interquartile range.
A multilevel ‘random-slope/random-intercept’ model 
was used to model FEV1 change over time. Fixed effects 
with 95% confidence intervals were estimated for the 
number of years with ≥1 exacerbation, both analyzed as 
categorical (0,1,2,3,4,5,6) and continuous variable (with 
the latter showing a slightly better model fit when calcu-
lated as Akaike Information Criterion (AIC)). The associa-
tions with both intercept (FEV1 at index date, ie, 
spirometry at time of COPD diagnosis) and slope (FEV1 
decline over time) were studied. An interaction term of 
follow-up time with the number of years with exacerba-
tions represented the association of exposure with slope of 
FEV1 decline. Random effects were included allowing 
each patient’s change in lung function over time to be 
scattered around the population average trajectory, 
assuming that the errors were independent and normally 
distributed. The model also included sex, age, height, 
weight, and smoking status as covariates, including an 
interaction term with time, to adjust for potential con-
founding by other well-known risk factors of lung function 
decline.9 We have also tested whether the presence of 
comorbidities changed the associations by including the 
variables into the model separately (<2% change in coeffi-
cient). Mean marginal FEV1 decline and FEV1 at index 
date with 95% confidence intervals were visualized for 
each possible number of years the patients experienced 
any exacerbation within the 6 years of follow-up analyzing 
a categorical variable.
Given the recent, albeit controversial evidence on the 
effect of ICS on slope of decline we also performed analyses 
including an interaction term with a time-varying variable 
indicating whether the most recent therapy prior to the lung 
function measurement (within previous 120 days) contained 
ICS or not.
Sensitivity analyses were conducted excluding FEV1 
measurements taken within 2 weeks before or after the 
occurrence of an exacerbation and excluding patients who 
ever had a diagnosis of asthma prior to index date.10,11
Results
Patient Characteristics
The flowchart for patient selection is depicted in Figure 1. 
Following exclusion and inclusion criteria, 11,337 patients 
who had at least 6 years of electronic medical data since 
initiation of maintenance therapy were identified. Of these, 
43% had already started inhaler maintenance therapy at 
index date and 42% started in the first year afterwards.
Patient demographics are shown in Table 2 and 
Supplementary Table E1. Patients were on average 65 
years old at index date (FEV1 around time of first COPD 
diagnosis) with almost even distribution of gender (51% 
men). A total of 52.4% of patients were indicated as ex- 
smokers in the baseline period; 31% continued smoking, 
and 36% were sustained quitters after index date.
Most patients had no (31.5%) or only one year (23.2%) 
with ≥1 exacerbation in the first 6 years after therapy 
initiation (Figure 2). A total of 45.1%, 28.5%, 16.9%, 
8.7% and 3.4% had ≥2, ≥3, ≥4, ≥5 and ≥6 years with ≥1 
exacerbation, respectively (mean (±standard deviation): 
1.7 (±1.7) years).
A total of 35% of patients experienced at least one year 
with frequent exacerbations (≥2 exacerbations per year) 
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during the first 6 years after maintenance therapy, and 
0.8% experienced frequent exacerbations in every year 
throughout the 6 years (Figure 2).
Association Between the Number of 
Years with Exacerbation and FEV1 
Decline
Compared to patients without exacerbations, mean FEV1 
decline over time was greater for patients who experienced 
exacerbations after initiation of maintenance treatment 
(Figure 3). The mean annual FEV1 decline accelerated by 
1.50 mL/year (95% Confidence Interval 1.02; 1.98, p<0.001) 
with every additional year with ≥1 exacerbation from 
31.0 mL/year in subjects without any exacerbation to 
40.0 mL/year in patients experiencing ≥1 exacerbation 
every year, when analyzed as a continuous variable. 
A greater effect was observed when counting the number of 
years with multiple (≥2) exacerbations with a 2.19 mL/year 
(95% CI 1.51; 2.88, p<0.001) excess decline with every 
one year increase in experiencing ≥2 exacerbations.
Association Between the Number of 
Years with Exacerbation Events and Fev1 
at the Time of First Clinical COPD 
Diagnosis
Patients with more years with ≥1 exacerbation had a lower 
mean FEV1 at first diagnosis: 14.7 mL (11.7; 17.8, p<0.001) 
lower with every additional year with ≥1 exacerbation. 
When counting years with ≥2 exacerbations, FEV1 at 
index date was 16.5 mL (12.1; 20.8, p<0.001) lower for 
every additional year with ≥2 exacerbations) (Figure 4).
Treatment with or without ICS During 
Follow-Up
Of 82,956 spirometry measurements recorded, 52% were 
performed after a recent prescription for ICS; 35% of 
patients already had ICS prescribed prior to spirometry 
performed around first diagnosis. Recent ICS therapy did 
not influence the observed acceleration of FEV1 decline 
with an increasing number of years with exacerbation 
(p-value for interaction term of time with the continuous 
variable of number of years with ≥1 exacerbation and 
presence of ICS prescription within 120 days prior to 
FEV1 measurement = 0.961) (Supplementary Figure E1). 
However, treatment with ICS was associated with 
a slightly higher FEV1 at the time of first COPD diagnosis, 
in particular for patients who had no exacerbations after 
initiating maintenance therapy (31 mL (95% confidence 
interval: 23 to 39) higher when treated with ICS) (p-value 
interaction term of intercept with variables =0.051) 
(Supplementary Figure E1).
We have found no change in associations after adjust-
ment for baseline comorbidities diagnosed ever.
Sensitivity Analyses
A sensitivity analysis excluding 5647 (6.8%) FEV1 
values recorded within a window of 2 weeks before or 
Figure 1 Patient selection flowchart.
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Table 2 Patient Characteristics
Variable Total (N= 11,337)
Spirometry follow-up after index date (ID), years Median (IQR) 8.2 (7.0;10.1)
Age (years) at index date Mean (SD) 65.2 (10.0)
Sex Male, n (%) 5771 (50.9)
Body mass index, closest to index date Mean (SD) 27.4 (5.6)
Underweight, n (%) 329 (2.9)
Normal Weight, n (%) 3656 (32.2)
Overweight, n (%) 4143 (36.5)
Obese, n (%) 3209 (28.3)
Baseline smoking status, closest to index date N (% non-missing) 10,411 (91.8)
Ex-smoker, n (%) 5454 (52.4)
Smoking status up to 5 years of follow-up after index date N (% non-missing) 10,462 (92.3)
Sustained quitter, n (%) 3785 (36.2)
Intermittent quitter, n (%) 3467 (33.1)
Continuous smoker, n (%) 3210 (30.7)
Asthma diagnosis prior to COPD diagnosis Ever, n (%) 1423 (12.6)
GOLD stage of airflow limitation at index date GOLD 2: (moderate: 50% ≤ FEV1 
<80%), n (%)
10,116 (89.2)
mMRC dyspnea scale N (% non-missing) 10,438 (92.1)
0, n (%) 1913 (18.3)
1, n (%) 5058 (48.5)
2, n (%) 2513 (24.1)
3, n (%) 833 (8.0)
4, n (%) 121 (1.2)
GOLD group (2017 definition, based on mMRC and exacerbations in last year) 
at index date
N (% non-missing) 10,438 (92.1)
A, n (%) 5641 (54.0)
B, n (%) 2762 (26.5)
C, n (%) 1330 (12.7)
D, n (%) 705 (6.8)
COPD exacerbations in year prior to index date Mean (SD) 0.8 (1.1)
0, n (%) 6298 (55.6)
1, n (%) 2946 (26.0)
2, n (%) 1241 (10.9)
3, n (%) 505 (4.5)
≥4, n (%) 347 (3.1)
Highest level of maintenance therapy initiated during follow-up LAMA or LABA 593 (5.2)
ICS monotherapy 1081 (9.5)
ICS+(LABA or LAMA) 2901 (25.6)
LABA+LAMA 462 (4.1)
Triple therapy 6300 (55.6)
Blood eosinophil count, x109 cells/liter, closest within 2 years of highest 
maintenance therapy initiation
N (% non-missing) 6171 (54.4)
<0.15, n (%) 1924 (31.2)
0.15–0.34, n (%) 3062 (49.6)
≥0.35, n (%) 1185 (19.2)
Abbreviations: IQR, interquartile range; SD, standard deviation; mMRC, modified medical research council; GOLD, global initiatives for chronic obstructive lung disease; 
FEV1, forced expiratory volume in one second.
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after the occurrence of an exacerbation showed similar 
results for the association of years with ≥1 exacerbation 
with the rate of FEV1 decline and FEV1 at index date 
(Supplementary Figure E2). No relevant differences in 
results were observed after excluding 1423 (12.6%) 
patients who ever had a diagnosis of asthma recorded 




This study is, to the extent of our knowledge, the first to 
show that a higher long-term burden of COPD exacerba-
tions while receiving maintenance treatment is associated 
with accelerated lung function decline over time. Patients 
with a higher exacerbation burden already had a lower 
lung function at the time of first clinical diagnosis of 
Figure 2 Distribution of the number of years with ≥1 and ≥2 COPD exacerbations after initiation of maintenance therapy.
Figure 3 Marginal mean decline in FEV1 (mL/year) with 95% confidence interval by the number of years patients experienced ≥1 (left) and ≥2 (right) COPD exacerbations 
during 6 years after initiation of maintenance therapy.
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mild to moderate COPD, ie, FEV1 was on average 15 mL 
lower with every additional year that patients experienced 
≥1 exacerbation after initiation of maintenance therapy. 
There was no evidence that treatment with ICS affects 
the association between lung function decline and exacer-
bation frequency.
Our findings suggest that the long-term exacerbation 
burden that patients experience despite receiving mainte-
nance therapy is likely to be an important indicator for the 
clinical course of COPD. It may indicate the degree of 
underlying chronic airway inflammation, causing tissue 
destruction and progressive airflow restriction. Whether 
exacerbations cause excess decline or are the consequence 
of a period of more severe airway inflammation leading to 
potentially irreversible airflow restriction remains unclear. 
If inflammation does indeed play a key role in exacerba-
tion, it will be pertinent to target inflammation at the ear-
liest stages of the disease to change its clinical course.
Previous studies have reported an association between 
exacerbation frequency and lung function decline.11–14 
A recent observational study demonstrated the association 
between acute exacerbations and lung function decline 
over 5 years to be greatest in patients with mild COPD 
(GOLD stage I), where each exacerbation was associated 
with an additional 23 mL/year decline (95% confidence 
interval: 2 to 44).4 However, this was based on a relatively 
small population, and thus it was not possible to derive 
accurate estimates. The current study adds to our knowl-
edge on the impact of increased COPD exacerbation bur-
den, expressed as the number of years with exacerbation 
under maintenance therapy, on lung function decline in 
patients with mild-moderate COPD.
We observed a dose-response relationship between the 
number of years with exacerbations and lung function 
decline. Although the actual acceleration of FEV1 decline 
is relatively small for most patients with COPD who 
occasionally experience exacerbations, differences become 
relevant for long-term frequent exacerbators who do not 
seem to respond to maintenance therapy. For example, 
a patient aged 65 years at the time of COPD diagnosis, 
who had at least one exacerbation every year lost 9 mL 
extra above 31 mL/year, which is 29% more than similar 
patients without exacerbations. The associations may be 
stronger for severe exacerbations leading to hospitaliza-
tion, which may be revealed by future studies.
Strengths
This study was conducted using two large primary care 
databases consisting of high-quality electronic medical 
records. This enabled research with a large sample size of 
COPD patients encompassing a long period of observation.
The utilization of real-life patient records also alludes to 
results that are more representative of the general COPD 
patient population, in contrast to Randomized Controlled 
Figure 4 Marginal mean FEV1 (mL) with 95% confidence interval at the time of first clinical COPD diagnosis by the number of years patients experienced ≥1 (left) and ≥2 
(right) COPD exacerbations during 6 years after initiation of maintenance therapy.
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trials (RCTs). Only a median of 23% patients with confirmed 
COPD diagnosis within the OPRCD would be eligible for 
inclusion to RCTs.15 This is in agreement with results from 
prior studies also reporting the low eligibility rate of the 
general COPD patient population for inclusion to RCTs.15–18
Limitations
There are several limitations of this study that warrant con-
sideration. Firstly, we have no accurate information available 
whether FEV1 values were measured post-bronchodilation. 
Regardless, in the UK, the Quality and Outcomes 
Framework (QOF), a financial incentive system for the provi-
sion of quality primary care medical services within general 
practice, requires post-bronchodilator spirometry at the time of 
diagnosis and annual monitoring of spirometry.19 In the UK, 
spirometry should be quality assured and only be performed 
by people who have been trained and assessed to satisfy the 
standards set by the Association for Respiratory Technology 
and Physiology (ARTP) or equivalent. However, this frame-
work to further improve the quality of diagnostic spirometry 
has only been introduced recently (September 2016) and, as of 
the writing of this manuscript, participation in spirometry 
training has not been made mandatory. Thus, quality of spiro-
metry cannot be assured.
Secondly, like other observational studies using routi-
nely collected patient data, this study is also susceptible to 
data inaccuracy and incompleteness20,21 within the 
OPCRD and CPRD, despite the extensive quality control 
and validity checks. The current study only reports asso-
ciations without any judgment on the causal relationship 
between lung function decline and exacerbation. We also 
do not account for potential confounding due to the impact 
of changes in prescription within the follow-up period.
Lastly, the current study describes how doctors could 
use easily accessible information on the long-term burden 
of exacerbations to identify patients at risk of accelerated 
lung function decline, even before COPD has been diag-
nosed, and does not assess the impact of blood eosinophil 
counts and type of therapy on lung function decline. In 
a separate study, we report that COPD exacerbations are 
associated with a more rapid loss of lung function among 
patients with elevated blood eosinophils (≥350 cells/μL), 
when they are not treated with ICS therapy.22 This sug-
gests a full blood count measurement to be the next step 
after spirometry for patients with a high exacerbation 
burden shows reduced lung function.
Conclusion
In conclusion, patients who experienced a greater exacerba-
tion burden in spite of maintenance therapy had worse lung 
function when first diagnosed with mild to moderate COPD 
and had a more rapid lung function decline thereafter.
Our results stress the importance of optimal therapeutic 
interventions earlier in the course of the disease to reduce 
the underlying airway inflammation and to prevent irre-
versible airway remodeling leading to both exacerbations 
and fast lung function decline. Further research is required 
to understand whether lung function deterioration after 
exacerbation is permanent or partial reversibility of the 
lung function can be recouped with more aggressive and 
more effective treatment.
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randomized control trial; SD, standard deviation; UK, United 
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